Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. - Wikidata - wikimedia - TriplyDB

Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.

Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.

http://www.wikidata.org/entity/Q46941948

about

Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective Reducing the burden of Herpes Zoster in Italy Cost-effectiveness of vaccination against herpes zoster.ARIZONA study: is the risk of post-herpetic neuralgia and its burden increased in the most elderly patients?Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.The humanistic, economic and societal burden of herpes zoster in Europe: a critical review Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany Herpes Zoster Immunization in Older Adults Has Big Benefits.Preventing and managing herpes zoster: key actions to foster healthy aging.Herpes zoster vaccine: A health economic evaluation for Switzerland.Shingles (Herpes Zoster) Vaccine (Zostavax(®)): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia.COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS.Cost-effectiveness of a herpes zoster vaccination program among the French elderly people Clinical and economic impact of herpes zoster vaccination in elderly in Italy.Herpes zoster immunization in older adults has big benefits.

P2860

Q26781940-8D22C32C-E22F-4938-8027-8E56278FB0CE Q26998625-A6F13D45-010B-491E-9A87-99796A04678A Q34291150-079FF2BD-5A06-49CB-B552-CA8C93C89726 Q34667569-5CB96A08-4A20-4732-9D0A-5F4722968C29 Q35000186-B903D6CD-DD7A-4B05-9399-E953CC621745 Q35147612-D77A0881-ED7C-4E99-A1A8-43EEA2AE0E3D Q35652212-7DFDC1E7-F1B6-438E-96CE-8EFF506EA897 Q35887517-DA06D8AD-E005-4093-AA0E-5B15B14EE4F5 Q38384783-024951D1-789E-4258-BF5A-51E5C2FB1743 Q38416454-EFF3F593-56CB-456A-A182-93C12AE26420 Q38798312-F62475BD-72B6-4842-AF24-27F8F436487A Q38836789-F705E155-C81D-478E-941C-09FAC52F9409 Q39394780-D4762E93-E89D-4C2C-BB96-3BA3F43C3B0E Q40591031-DF77A80D-1C1D-4D28-B86A-830174D7DB97 Q45937750-6EE4C01F-A6D9-4D2B-9344-78EC4174D066 Q49024900-8E124A50-26B0-4245-9236-2E6D3C150F21

P2860

Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.

http://www.wikidata.org/entity/Q46941948

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Vaccination against herpes zos ...... a cost-effectiveness analysis.

@en

Vaccination against herpes zos ...... a cost-effectiveness analysis.

@nl

type

label

Vaccination against herpes zos ...... a cost-effectiveness analysis.

@en

Vaccination against herpes zos ...... a cost-effectiveness analysis.

@nl

prefLabel

Vaccination against herpes zos ...... a cost-effectiveness analysis.

@en

Vaccination against herpes zos ...... a cost-effectiveness analysis.

@nl

P1433

Q46941948-463E5B33-819A-47E6-A2FA-88DB301FD878

P1476

Q46941948-C109F86F-A13B-447C-AC87-7EF81D72F9AD

P2093

Q46941948-00616467-44E7-45A4-99F9-850C3842316E

Q46941948-15DBE50D-234C-4DC0-9BFD-2B18123DAF57

Q46941948-773E5722-FFA7-42DC-AA5D-D98FF1B1E7C3

Q46941948-78C407BE-CC09-4FB7-8A0F-1C9AE518DD69

Q46941948-D513CAAF-10CB-42D4-9AD3-26A8A238BDFA

Q46941948-FE42DC7F-46FF-42A7-A4F7-93267564D2FD

P2860

Q46941948-06801AD5-BB96-47B5-A1D6-FECB05B50F8E

Q46941948-0A9FFB33-CC29-4440-A1F2-12367DD183CE

Q46941948-1A067889-2F7A-431E-ACFC-26DAD753274D

Q46941948-1D00F56E-F41B-4733-8E57-8AC2E6140B79

Q46941948-21B35D97-7D06-42B2-B3D8-E5D3DED51C76

Q46941948-281092D8-8344-4562-8F26-71E564A679B8

Q46941948-2C7B5626-63D2-4BAF-864C-2E8B6BCFD2C0

Q46941948-34F99324-01C6-4C8A-A045-3BBA9B323E20

Q46941948-3A819850-E830-44F9-9ADE-35321C850F72

Q46941948-430F0E78-8A30-49E3-90D1-B1321A6D2F41

P304

Q46941948-54989318-535C-4F1D-BFD1-1CF670718E84

P31

Q46941948-65179C34-34EC-4BDF-9D79-9115A7FBD194

P356

Q46941948-FABF814C-143B-4B2A-86C7-801325D21AA4

P433

Q46941948-1E5EE9A8-5D59-4E38-A294-9D1D58ADF257

P478

Q46941948-4F5B36F8-8971-4DFB-A60C-F294946EBC4E

P577

Q46941948-4102DD52-4985-4E5B-9617-7B25A6CB87A6

P5875

Q46941948-89437412-AF2F-4E84-B264-32C51E8E0E55

P698

Q46941948-5241EBA6-919B-4BED-9B48-089B8F9DEF54

P356

P1433

Expert Review of Pharmacoeconomics & Outcomes Research

P1476

Vaccination against herpes zos ...... a cost-effectiveness analysis.

@en

P2093

Aline Gauthier

http://www.w3.org/2001/XMLSchema#string

Emmanuelle Préaud

http://www.w3.org/2001/XMLSchema#string

Gérard Duru

http://www.w3.org/2001/XMLSchema#string

Karine Bloch

http://www.w3.org/2001/XMLSchema#string

Lieven Annemans

http://www.w3.org/2001/XMLSchema#string

Xavier Bresse

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up

Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction

A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults

Vaccination against Herpes Zoster and Postherpetic Neuralgia

Acute Pain in Herpes Zoster and Its Impact on Health-Related Quality of Life

[Vaccination against seasonal influenza in France in 2010 and 2011: decrease of coverage rates and associated factors].

The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.

Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands.

A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK.

P304

393-406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERP.13.19

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236088838

http://www.w3.org/2001/XMLSchema#string

P698

23537397

http://www.w3.org/2001/XMLSchema#string